➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
Boehringer Ingelheim
Baxter
Mallinckrodt

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEFTAZIDIME IN DEXTROSE CONTAINER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ceftazidime In Dextrose Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00173901 ↗ Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status National Taiwan University Hospital Phase 4 2001-03-01 The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
NCT00210964 ↗ Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 2005-04-01 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00229008 ↗ Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 2005-11-01 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Baxter Healthcare Corporation Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated GlaxoSmithKline Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ceftazidime In Dextrose Container

Condition Name

Condition Name for Ceftazidime In Dextrose Container
Intervention Trials
Pneumonia 5
Complicated Intra-Abdominal Infection 4
Cystic Fibrosis 4
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ceftazidime In Dextrose Container
Intervention Trials
Infection 17
Communicable Diseases 15
Pneumonia 9
Urinary Tract Infections 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ceftazidime In Dextrose Container

Trials by Country

Trials by Country for Ceftazidime In Dextrose Container
Location Trials
United States 86
Spain 11
India 11
Poland 8
Czech Republic 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ceftazidime In Dextrose Container
Location Trials
California 12
Ohio 8
Michigan 6
Texas 5
New Jersey 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ceftazidime In Dextrose Container

Clinical Trial Phase

Clinical Trial Phase for Ceftazidime In Dextrose Container
Clinical Trial Phase Trials
Phase 4 12
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ceftazidime In Dextrose Container
Clinical Trial Phase Trials
Completed 29
Not yet recruiting 10
Recruiting 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ceftazidime In Dextrose Container

Sponsor Name

Sponsor Name for Ceftazidime In Dextrose Container
Sponsor Trials
AstraZeneca 17
Forest Laboratories 7
Pfizer 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ceftazidime In Dextrose Container
Sponsor Trials
Industry 44
Other 38
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Dow
Baxter
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.